Our novel aerosol R&D technology reduces risk, minimizes errors and accelerates the development of inhalable drugs. It gives researchers full control of their aerosol—and results.Read more
PreciseInhale: finally a novel R&D tool that puts inhalation scientists in full control of their aerosol—and their results
Uniquely, PreciseInhale generates aerosol in precise, repeatable, controlled doses. This Precision Dosing methodology eliminates errors, accelerates research and prevents clinical failure—generating data of unparalleled quality and precision.
BREATHING NEW LIFE INTO INHALATION R&D
Our novel R&D technology is one of the most advanced breakthroughs in lung research for decades. For pharma companies and toxicological researchers the accuracy and precision of the lung data it generates is an essential tool for seizing fast-growing new opportunities in inhalation.
THE WORLD IS INHALING MORE MEDICINES
The need for precision lung data for drug development has never been greater. Our technology delivers that data:
The race is on for generics: From Advair to Xolair many of the world’s most widely-used inhaled medicines are now off-patent, with more to come. For generic inhalable researchers, precise, go / no-go lung data early-on eliminates errors and accelerates drug development.
New treatments on the rise: Both asthma and COPD are increasing dramatically—and the pipeline for new inhalable treatments is growing with them.
New biologics and inhalables: Research into inhaled antibiotics for lung infections, like the recently approved new inhalable antibiotic for cystic fibrosis, is growing fast. The speed and immediacy of the lung as an administration point is being explored worldwide.
ENVIRONMENTAL LUNG RESEARCH—AND THE POWER OF PRECISION
Environmental and toxicological research is in our DNA. Our founder and CSO Per Gerde is Associate Professor of Inhalation Toxicology at the Institute of Environmental Medicine in Karolinska Institutet. As investment into better air pollution research grows, and even becomes mandatory in some countries, environmental and tox researchers are turning to our technology to measure precisely how particles behave in our lungs when we inhale them
Our customers are inhalation leaders in the field of inhalation—and so are we! We believe PreciseInhale will become the standard R&D tool for all inhalation research worldwide. The calibre of our customers confirms it.
THE POWER OF PRECISION, THE ART OF THE AEROSOL
PreciseInhale eliminates errors, accelerates research and prevents clinical failure. It is a historic breakthrough in lung research and development. To explore the science of PreciseInhale and Precision Dosing, read more below.
- 27 Sep, 2019
Inhalation Sciences' PreciseInhale delivers exceptional precision in ground-breaking inhalable nicotine study24 Sep, 2019
- 13 Sep, 2019
- 14 Jun 2019
Inhalation Sciences sign agreement with UK IVD consultants Pathaway at Kings College London customer event13 Jun 2019
“More precision, less risk, faster drug development” ISAB CEO Lena Heffler on how clinical validation will power PreciseInhale28 May 2019